Catherine McDonald
Psychiatry · Lafayette, LANPI 1235183468
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 237 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AbbVie at 31.3% of the total. Reporting peaked in 2023 at $1,539 and has fallen 78.7% since, to $328 in 2025. Among psychiatry clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 237 payments — averaging $25.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$744
- Otsuka America Pharmaceutical, Inc.$696
- Alkermes, Inc.$603
- Indivior Inc.$396
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$380
- plus $1K from 8 others
What the payments were for
- Food & beverage$6,105100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 88 | $1,908 |
| Johnson & Johnson | 31 | $744 |
| Otsuka America Pharmaceutical, Inc. | 13 | $696 |
| Alkermes, Inc. | 22 | $603 |
| Indivior Inc. | 28 | $396 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $380 |
| Teva Pharmaceuticals USA, Inc. | 18 | $327 |
| Neurocrine Biosciences, Inc. | 7 | $302 |
| Sunovion Pharmaceuticals Inc. | 10 | $234 |
| E.r. Squibb & Sons, L.L.C. | 4 | $137 |
| Corium, LLC | 1 | $123 |
| Axsome Therapeutics, Inc. | 1 | $118 |
| Idorsia Pharmaceuticals US Inc | 1 | $95 |
| Vanda Pharmaceuticals Inc. | 3 | $42 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$730
- ARISTADA$499
- LYBALVI$420
- REXULTI$356
- INVEGA SUSTENNA$237
- CAPLYTA$125
- ARISTADA INITIO$125
- Azstarys$123
- UZEDY$122
- ABILIFY MAINTENA$122
- Auvelity$118
- LATUDA$112
- INGREZZA$111
- INVEGA TRINZA$108
- INVEGA$108
- SPRAVATO$108
How this compares
$6,105 in reported general payments places this provider in the 90th percentile of 474 psychiatry providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 13 | $46,542 |
| VraylarCariprazine Hcl | 26 | $40,133 |
| PerserisRisperidone | 11 | $24,762 |
| Oxcarbazepine | 41 | $1,548 |
| Haloperidol Decanoate | 20 | $1,408 |
| Ziprasidone Hcl | 15 | $1,348 |
| Carbamazepine ErCarbamazepine | 12 | $1,254 |
| Armodafinil | 13 | $807 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 18 | $674 |
| Hydroxyzine Pamoate | 34 | $505 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 24 | $486 |
| Trazodone Hcl | 34 | $462 |
| Aripiprazole | 15 | $359 |
| Benztropine Mesylate | 18 | $315 |
| Bupropion XlBupropion Hcl | 24 | $294 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $744 | $46,54213 claims |
| AbbVieVraylar | $1,908 | $40,13326 claims |
| Indivior Inc.Perseris | $396 | $24,76211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 474 psychiatry providers in Louisiana.
Other psychiatry in Lafayette
- Edgardo ConcepcionLafayette$15K
- Bob WinstonLafayette$6K
- David DawesLafayette$5K
- Patrick HayesLake Charles$837K
- Maria CruseThibodaux$522K
- Larry WarnerBaton Rouge$495K
- Gregory BrownShreveport$495K
- Arwen PodestaNew Orleans$466K
- Jasjit SinghShreveport$420K
- Roger BrownMandeville$216K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.